Scholarlink

Objective <p>This study aimed to evaluate the efficacy and safety of upadacitinib in patients with refractory Behcet’s syndrome (BS).</p> Methods <p>A multicentre, single-arm trial was conducted from February 2023 to August 2025. Eligible patients had BS refractory to at least two immunosuppressive agents or one targeted therapy for a minimum of 6 months. Participants discontinued previous targeted therapies and received upadacitinib 15&#xa0;mg/day for up to 48 weeks, in addition to their ongoing glucocorticoid and immunosuppressant regimens. Clinical features, inflammatory markers, imaging findings, and treatment data were collected throughout follow-up. The primary endpoint was the overall response rate (ORR; complete response [CR] plus partial response [PR]) at 24 weeks.</p> Results <p>Twenty-seven patients (16 male; median age 36 years) were enrolled, with a median baseline BDCAF score of 4 (range: 2–7). Affected systems included the mucocutaneous, articular, gastrointestinal, cardiovascular, and ocular systems. The ORR at 24 weeks was 85.2% (23/27), comprising 16 CRs and 7 PRs. Significant reductions were observed in median BDCAF scores, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and glucocorticoid dosage by week 24. Among the 23 patients who achieved remission at week 24, median CRP and ESR levels at 48 weeks were significantly lower than those at 24 weeks. For clinical responses across different systems, CR was achieved in 3 (100.0%) with cardiovascular involvement, 5 (83.3%) with ocular symptoms, 10 (76.9%) with gastrointestinal involvement, 16 (59.3%) patients with mucocutaneous symptoms, and 1 (16.7%) with articular involvement at 24 weeks. Three patients experienced relapse during the follow-up. No serious adverse events were reported.</p> Conclusion <p>Upadacitinib represents a potential therapeutic option for patients with refractory BS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Upadacitinib for refractory Behcet’s syndrome: a multi-centre, single-arm trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月3日

查看全文
  • Jiachen Li,
  • Weiyi Xia,
  • Huijuan Ji,
  • Xiaoxin Gong,
  • Qi Dong,
  • Yanan Wu,
  • Longjun Wang,
  • Meixia Peng,
  • Sifan Geng,
  • Jingxuan Liu,
  • Ke Ma,
  • Qi Yu,
  • Xinglei Cui,
  • Yuanyuan Luo,
  • Wenhua Zhu,
  • Shumin Zhang,
  • Shi Chen,
  • Yuhui Li,
  • Zhanguo Li,
  • Tian Liu

摘要

Objective

This study aimed to evaluate the efficacy and safety of upadacitinib in patients with refractory Behcet’s syndrome (BS).

Methods

A multicentre, single-arm trial was conducted from February 2023 to August 2025. Eligible patients had BS refractory to at least two immunosuppressive agents or one targeted therapy for a minimum of 6 months. Participants discontinued previous targeted therapies and received upadacitinib 15 mg/day for up to 48 weeks, in addition to their ongoing glucocorticoid and immunosuppressant regimens. Clinical features, inflammatory markers, imaging findings, and treatment data were collected throughout follow-up. The primary endpoint was the overall response rate (ORR; complete response [CR] plus partial response [PR]) at 24 weeks.

Results

Twenty-seven patients (16 male; median age 36 years) were enrolled, with a median baseline BDCAF score of 4 (range: 2–7). Affected systems included the mucocutaneous, articular, gastrointestinal, cardiovascular, and ocular systems. The ORR at 24 weeks was 85.2% (23/27), comprising 16 CRs and 7 PRs. Significant reductions were observed in median BDCAF scores, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and glucocorticoid dosage by week 24. Among the 23 patients who achieved remission at week 24, median CRP and ESR levels at 48 weeks were significantly lower than those at 24 weeks. For clinical responses across different systems, CR was achieved in 3 (100.0%) with cardiovascular involvement, 5 (83.3%) with ocular symptoms, 10 (76.9%) with gastrointestinal involvement, 16 (59.3%) patients with mucocutaneous symptoms, and 1 (16.7%) with articular involvement at 24 weeks. Three patients experienced relapse during the follow-up. No serious adverse events were reported.

Conclusion

Upadacitinib represents a potential therapeutic option for patients with refractory BS.